78 related articles for article (PubMed ID: 8153348)
1. Safety of MR contrast media.
Olukotun AY
Radiology; 1994 May; 191(2):584-5. PubMed ID: 8153348
[No Abstract] [Full Text] [Related]
2. [Nephrotoxicity of contrast media in magnetic resonance tomography (MRI)].
Heuck A; Reiser M
Internist (Berl); 1997 Dec; 38(12):1234-5. PubMed ID: 9465330
[No Abstract] [Full Text] [Related]
3. Adverse reaction to intravenous gadoteridol.
Shellock FG; Hahn HP; Mink JH; Itskovich E
Radiology; 1993 Oct; 189(1):151-2. PubMed ID: 8372186
[TBL] [Abstract][Full Text] [Related]
4. [The Grenelle of MR contrast agents?].
Clément O
J Radiol; 2007 Nov; 88(11 Pt 1):1663. PubMed ID: 18065924
[No Abstract] [Full Text] [Related]
5. Safety of gadobenate dimeglumine (MultiHance): Summary of findings from clinical studies and postmarketing surveillance.
Shellock FG; Parker JR; Venetianer C; Pirovano G; Spinazzi A
Invest Radiol; 2006 Jun; 41(6):500-9. PubMed ID: 16763468
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the safety and efficacy of gadoteridol injection (a low osmolal magnetic resonance contrast agent). Clinical trials report.
DeSimone D; Morris M; Rhoda C; Lucas T; Zielonka J; Olukotun A; Carvlin M
Invest Radiol; 1991 Nov; 26 Suppl 1():S212-6; discussion S232-5. PubMed ID: 1808133
[No Abstract] [Full Text] [Related]
7. Clinical safety and efficacy of gadoteridol: a study in 411 patients with suspected intracranial and spinal disease.
Runge VM; Bradley WG; Brant-Zawadzki MN; Carvlin MJ; DeSimone DN; Dean BL; Dillon WP; Drayer BP; Flanders AE; Harms SE
Radiology; 1991 Dec; 181(3):701-9. PubMed ID: 1947085
[TBL] [Abstract][Full Text] [Related]
8. Response to the FDA's May 23, 2007, nephrogenic systemic fibrosis update.
Kanal E; Broome DR; Martin DR; Thomsen HS
Radiology; 2008 Jan; 246(1):11-4. PubMed ID: 17855656
[No Abstract] [Full Text] [Related]
9. Safety of gadobutrol, a new generation of contrast agents: experience from clinical trials and postmarketing surveillance.
Voth M; Rosenberg M; Breuer J
Invest Radiol; 2011 Nov; 46(11):663-71. PubMed ID: 21623211
[TBL] [Abstract][Full Text] [Related]
10. Considerations in the choice of contrast media for MR imaging.
Brasch RC; Bennett HF
Radiology; 1988 Mar; 166(3):897-9. PubMed ID: 3340795
[No Abstract] [Full Text] [Related]
11. Occurrence of adverse reactions to gadolinium-based contrast material and management of patients at increased risk: a survey of the American Society of Neuroradiology Fellowship Directors.
Murphy KP; Szopinski KT; Cohan RH; Mermillod B; Ellis JH
Acad Radiol; 1999 Nov; 6(11):656-64. PubMed ID: 10894068
[TBL] [Abstract][Full Text] [Related]
12. Severe anaphylactoid shock secondary to gadolinium contrast media.
Simons CW; Benouni S; Gibbon G; Klaustermeyer W
Ann Allergy Asthma Immunol; 2009 Oct; 103(4):359-60. PubMed ID: 19852205
[No Abstract] [Full Text] [Related]
13. Clinical safety of gadopentetate dimeglumine.
Nelson KL; Gifford LM; Lauber-Huber C; Gross CA; Lasser TA
Radiology; 1995 Aug; 196(2):439-43. PubMed ID: 7617858
[TBL] [Abstract][Full Text] [Related]
14. Safety of magnetic resonance imaging contrast agents.
Shellock FG; Kanal E
J Magn Reson Imaging; 1999 Sep; 10(3):477-84. PubMed ID: 10508312
[TBL] [Abstract][Full Text] [Related]
15. Clinical safety and diagnostic value of the gadolinium chelate gadoterate meglumine (Gd-DOTA).
Herborn CU; Honold E; Wolf M; Kemper J; Kinner S; Adam G; Barkhausen J
Invest Radiol; 2007 Jan; 42(1):58-62. PubMed ID: 17213750
[TBL] [Abstract][Full Text] [Related]
16. Assessment of utilization and pharmacovigilance based on spontaneous adverse event reporting of gadopentetate dimeglumine as a magnetic resonance contrast agent after 45 million administrations and 15 years of clinical use.
Knopp MV; Balzer T; Esser M; Kashanian FK; Paul P; Niendorf HP
Invest Radiol; 2006 Jun; 41(6):491-9. PubMed ID: 16763467
[TBL] [Abstract][Full Text] [Related]
17. Acute renal failure after arteriography with a gadolinium-based contrast agent.
Gemery J; Idelson B; Reid S; Yucel EK; Pagan-Marin H; Ali S; Casserly L
AJR Am J Roentgenol; 1998 Nov; 171(5):1277-8. PubMed ID: 9798860
[No Abstract] [Full Text] [Related]
18. Epinephrine administration for severe adverse reactions to contrast agents.
Samett EJ; Espinosa GA
Radiology; 1995 Sep; 196(3):879. PubMed ID: 7644663
[No Abstract] [Full Text] [Related]
19. How should nephrologists approach gadolinium-based contrast imaging in patients with kidney disease?
Perazella MA
Clin J Am Soc Nephrol; 2008 May; 3(3):649-51. PubMed ID: 18385396
[No Abstract] [Full Text] [Related]
20. Safety of gadoteridol injection: U.S. clinical trial experience.
Olukotun AY; Parker JR; Meeks MJ; Lucas MA; Fowler DR; Lucas TR
J Magn Reson Imaging; 1995; 5(1):17-25. PubMed ID: 7696805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
